These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10838574)

  • 41. A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis.
    Silo-Suh L; Suh SJ; Sokol PA; Ohman DE
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15699-704. PubMed ID: 12426404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.
    López-Causapé C; Oliver A
    Future Microbiol; 2017 Dec; 12():1445-1448. PubMed ID: 29068237
    [No Abstract]   [Full Text] [Related]  

  • 43. Lung infections. 3. Pseudomonas aeruginosa and other related species.
    Wilson R; Dowling RB
    Thorax; 1998 Mar; 53(3):213-9. PubMed ID: 9659359
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis.
    Goldberg JB; Pier GB
    Trends Microbiol; 2000 Nov; 8(11):514-20. PubMed ID: 11121762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular genetics of exopolysaccharide production by mucoid Pseudomonas aeruginosa.
    Ohman DE
    Eur J Clin Microbiol; 1986 Feb; 5(1):6-10. PubMed ID: 3009178
    [No Abstract]   [Full Text] [Related]  

  • 47. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
    Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
    BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection.
    Costerton JW
    Trends Microbiol; 2001 Feb; 9(2):50-2. PubMed ID: 11173226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.
    Buret A; Cripps AW
    Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651
    [No Abstract]   [Full Text] [Related]  

  • 50. Antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Van Devanter DR
    Respiration; 2007; 74(3):356; author reply 357. PubMed ID: 17204830
    [No Abstract]   [Full Text] [Related]  

  • 51. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Marshall BC
    Am J Respir Crit Care Med; 2004 Apr; 169(7):781-2. PubMed ID: 15044219
    [No Abstract]   [Full Text] [Related]  

  • 52. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibiotic tolerance induced by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Andrés MT; Viejo-Diaz M; Pérez F; Fierro JF
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1613-6. PubMed ID: 15793153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A.
    Zhang S; McCormack FX; Levesque RC; O'Toole GA; Lau GW
    PLoS One; 2007 Jun; 2(6):e564. PubMed ID: 17593964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression analysis of a highly adherent and cytotoxic small colony variant of Pseudomonas aeruginosa isolated from a lung of a patient with cystic fibrosis.
    von Götz F; Häussler S; Jordan D; Saravanamuthu SS; Wehmhöner D; Strüssmann A; Lauber J; Attree I; Buer J; Tümmler B; Steinmetz I
    J Bacteriol; 2004 Jun; 186(12):3837-47. PubMed ID: 15175297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of efflux pump inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Coban AY; Tanriverdi Cayci Y; Erturan Z; Durupinar B
    J Chemother; 2009 Nov; 21(5):592-4. PubMed ID: 19933053
    [No Abstract]   [Full Text] [Related]  

  • 58. Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
    Lucca F; Guarnieri M; Ros M; Muffato G; Rigoli R; Da Dalt L
    Clin Respir J; 2018 Jul; 12(7):2189-2196. PubMed ID: 29498795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional characterization of pfm in protein secretion and lung infection of Pseudomonas aeruginosa.
    Bai F; Xu H; Zhang Q; Qi X; Mou R; Bai G; Qiao M
    Can J Microbiol; 2011 Oct; 57(10):829-37. PubMed ID: 21950738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
    Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
    Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.